These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 29355955)

  • 1. Complex neuroprotective and neurotoxic effects of histone deacetylases.
    Thomas EA; D'Mello SR
    J Neurochem; 2018 Apr; 145(2):96-110. PubMed ID: 29355955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Feb; 243():117278. PubMed ID: 31926248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders.
    Hahnen E; Hauke J; Tränkle C; Eyüpoglu IY; Wirth B; Blümcke I
    Expert Opin Investig Drugs; 2008 Feb; 17(2):169-84. PubMed ID: 18230051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.
    Sharma S; Sarathlal KC; Taliyan R
    CNS Neurol Disord Drug Targets; 2019; 18(1):11-18. PubMed ID: 30289079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
    Simões-Pires C; Zwick V; Nurisso A; Schenker E; Carrupt PA; Cuendet M
    Mol Neurodegener; 2013 Jan; 8():7. PubMed ID: 23356410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise.
    Mai A; Rotili D; Valente S; Kazantsev AG
    Curr Pharm Des; 2009; 15(34):3940-57. PubMed ID: 19751207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylases: focus on the nervous system.
    Morrison BE; Majdzadeh N; D'Mello SR
    Cell Mol Life Sci; 2007 Sep; 64(17):2258-69. PubMed ID: 17530170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple roles of HDAC inhibition in neurodegenerative conditions.
    Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
    Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylases as targets for the treatment of human neurodegenerative diseases.
    D'Mello SR
    Drug News Perspect; 2009 Nov; 22(9):513-24. PubMed ID: 20072728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human neuronal cells: epigenetic aspects.
    Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
    Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective.
    Kumar V; Kundu S; Singh A; Singh S
    Curr Neuropharmacol; 2022; 20(1):158-178. PubMed ID: 34151764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic analysis identifies NPTX1 and HIP1R as potential targets of histone deacetylase-3-mediated neurodegeneration.
    Qu Z; D'Mello SR
    Exp Biol Med (Maywood); 2018 Apr; 243(7):627-638. PubMed ID: 29486577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration.
    Trüe O; Matthias P
    Immunol Cell Biol; 2012 Jan; 90(1):78-84. PubMed ID: 22124372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirtuin deacetylases in neurodegenerative diseases of aging.
    Herskovits AZ; Guarente L
    Cell Res; 2013 Jun; 23(6):746-58. PubMed ID: 23689277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases.
    Tago T; Toyohara J
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.